EFEK TERAPI PURIFIED PROTEIN DERIVATIVE TERHADAP KADAR INTERLEUKIN-12 SERUM PASIEN KUTIL ANOGENITAL
DOI:
https://doi.org/10.33820/mdvi.v49i4.413Keywords:
Imunoterapi, interleukin-12, kutil anogenital, purified protein derivativeAbstract
Anogenital warts (AGWs) are benign epithelial proliferation of the skin/mucosa, caused by human papillomavirus (HPV), with clinical manifestation of warts in the genital/perianal areas. Cellular immunity plays a role in the elimination of HPV, which characterized by the expression of cytokines with Thelper (Th)-1 cell pattern, namely interleukin (IL)-12 which will increases Tcell proliferation and differentiation into Th-1, pro-inflammatory cytokines secretion, also induce natural killer cells to increase proliferation and pro-inflammatory cytokines. In in vitro studies, PPD increased IL-12 expression in serum verruca vulgaris patients (p<0,05) compared to control. There are no study of serum IL-12 levels in AGWs petients who received intralesional PPD injection in Indonesia, so this is the aim of this study. This research isone group pre- and post-test design based on an experimental analytic study. The samples were 14 serum of AGWs patients before and after receiving PPD therapy. Serum IL-12 levels meassured by enzyme linked immunosorbent assay. Results showedserum IL-12 levels before receiving therapy was 45.73±53.186pg/ml. After receiving PPD therapy, serum IL-12 levels increased by an average of 45.9pg/ml, became 91.68±79.321pg/ml (p=0,158). As conclusion,level of IL-12 in the serum of AGWs patients does not increase after receiving PPD therapy.
Downloads
References
2. Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC infect Dis. 2013;13(1):3
3. Kosen S, Andrijono A, Ocviyanti S, Indriatmi W. The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia. Asian Pac J Cancer Prev. 2011;18(7):2011-7.
4. Tyring SK. Human papillomavirus infections: epidemiology, pathogenesis, and host immune response. J Am Acad Dermatol. 2000;43:S18-26.
5. Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol. 2001;8:209-20.
6. Stanley MA, Sterling JC. Host responses to infection with human papillomavirus. Curr Probl Dermatol. 2014;45:58-74.
7. Shaheen MA, Salem SA, Fouad DA, Elâ€Fatah AA. Intralesional tuberculin (PPD) versus measles, mumps, rubella (MMR) vaccine in treatment of multiple warts: a comparative clinical and immunological study. Dermatol Ther. 2015;28(4):194-200.
8. Abd-Elazeim FM, Mohammed GF, Fathy A, Mohamed RW. Evaluation of IL-12 serum level in patients with recalcitrant multiple common warts, treated by intralesional tuberculin antigen. J Dermatol Treat. 2014;25(3):264-7.
9. Abou-Taleb DAE, Abou-Taleb HA, El-Badawy O, Ahmed AO, Hassan AET, Awad SM. Intralesional vitamin D3 versus intralesional purified protein derivative in treatment of multiple warts: A comparative clinical and immunological study. Dermatol Ther. 2019;32(5):e13034.
10. Del Vecchio AM, Romanczuk H, Howley PM, Baker CC. Transient replication of human papillomavirus DNAs. J Virol 1992; 66(10): 5949-5958.
11. Hamza T, Barnet JB, Li B. Interleukin 12 a Key Immunoregulatory Cytokine in Infection Applications . Int. J. Mol. Sci. 2010;11,:789-806
12. El-Samahy MH, El-Shennawy DA, Labib SMW, Abdallah MA. Evaluation of serum interleukin-12 and interferon-c in patients with multiple warts treated with intralesional tuberculin injection. J Egypt Women Dermatol Soc. 2016;13:23–28
13. Youssef S.S, Diab H, Sallam M.A.N, Ahmed A. Evaluation of IL2 and IFN γ mRNA Gene Expression in Resistant Genital and Plantar Warts, Treated by Intralesional Tuberculin. Pan Arab League of Dermatologists. 2009;20:147–158.
14. Lowes M.A, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba L.C. Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells. J Invest Dermatol. 2008;128:1207–11.
